Hormone Replacement Therapy Global Market Report 2025

The hormone replacement therapy market size has grown strongly in recent years. It will grow from $25.06 billion in 2024 to $27.28 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. The growth during the historic period can be attributed to the rising prevalence of menopausal symptoms among aging women, increased awareness of hormone deficiency treatments, longer life expectancy and an aging population, growing global healthcare spending, and the increasing use of estrogen therapy in postmenopausal women.

The hormone replacement therapy market size is expected to see strong growth in the next few years. It will grow to $37.9 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth during the forecast period can be attributed to the increasing prevalence of hormonal disorders, heightened awareness of menopausal health, a growing aging population globally, expanded healthcare access in emerging markets, and a rising demand for minimally invasive treatment options. Key trends in this period include progress in bio-identical hormone formulations, advanced transdermal drug delivery technologies, the development of personalized hormone therapies based on genetic profiling, innovations in long-acting hormone injectables, and advancements in telehealth integration for managing hormone therapy.

The growing number of postmenopausal women is expected to drive the expansion of the hormone replacement therapy market in the future. Postmenopausal women are those who have permanently ceased menstruation due to the natural reduction of reproductive hormones, usually occurring 12 months after their last period. This increase in postmenopausal women is linked to rising life expectancy, as women are living longer, leading to a larger aging female population undergoing menopause. Hormone replacement therapy benefits postmenopausal women by easing common symptoms like hot flashes and night sweats, thereby enhancing quality of life. It helps maintain hormonal balance through personalized treatments, reducing discomfort and supporting overall well-being. For example, in July 2022, Mayo Clinic Health System, a US-based healthcare organization, reported that the global population of menopausal and postmenopausal women is expected to reach 1.2 billion by 2030, with 47 million new cases annually. Consequently, the increasing number of postmenopausal women is fueling the growth of the hormone replacement therapy market.

Leading companies in the hormone replacement therapy market are concentrating on developing innovative formulations, including bio-identical hormone formulations, to enhance treatment effectiveness and patient adherence. Bio-identical hormone formulations utilize hormones that are chemically identical to those naturally produced by the human body, aiming to offer more natural and efficient symptom relief with fewer side effects. For example, in May 2024, Jagsonpal Pharmaceuticals Ltd., an India-based pharmaceutical firm, introduced MemUp, a bio-identical hormone replacement therapy (HRT). This advanced therapy combines estradiol and progesterone in a single, once-daily oral capsule. MemUp is designed to effectively relieve common menopausal symptoms such as hot flashes and night sweats while simplifying the treatment process to improve patient convenience and compliance.

In December 2024, Likarda, a US-based biotechnology firm, collaborated with VitalTE LifeSciences to develop extended-release injectable hormone therapies. This partnership seeks to improve patient convenience, increase treatment adherence, and provide a non-surgical alternative to conventional hormone delivery methods through innovative, long-acting formulations. VitalTE LifeSciences is a US-based biotechnology company focused on creating advanced hormone replacement therapy solutions.

Major players in the hormone replacement therapy market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Sanofi S.A., Abbott Laboratories, Novartis AG, GSK plc, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bausch Health Companies Inc., Cipla Inc., Gedeon Richter Plc., Lupin Limited, Orion Corporation, Halozyme Therapeutics Inc., Theramex HQ UK Limited.

North America was the largest region in the hormone replacement therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hormone replacement therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hormone replacement therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Hormone replacement therapy (HRT) is a medical procedure that provides the body with hormones that it no longer produces in adequate amounts. It is primarily used to ease symptoms linked to menopause, including hot flashes, night sweats, mood changes, and more.

The main types of hormone replacement therapy consist of estrogen replacement therapy, human growth hormone replacement therapy, thyroid hormone replacement therapy, testosterone replacement therapy, and others. Estrogen replacement therapy involves supplementing estrogen hormones to reduce symptoms caused by estrogen deficiency, such as those experienced during menopause. This therapy is applied for various conditions like menopause, hypothyroidism, male hypogonadism, growth hormone deficiency, among others, and can be administered orally, through the skin, by injection, and other methods. The primary distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and others.

The hormone replacement therapy market research report is one of a series of new reports that provides hormone replacement therapy market statistics, including the hormone replacement therapy industry global market size, regional shares, competitors with the hormone replacement therapy market share, detailed hormone replacement therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the hormone replacement therapy industry. This hormone replacement therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The hormone replacement therapy market includes revenues earned by entities through hormone level assessment, personalized treatment planning, prescription and administration of hormone therapies, patient monitoring, and follow-up care to manage symptoms related to hormonal imbalances. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.